~~<i id='AC54818D3A'><strike id='AC54818D3A'><tt id='AC54818D3A'><pre id='AC54818D3A'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：fashion 2025-09-29 23:10:15 Page View：17

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： STAT Readout: Friday, Oct. 20 biotech updates
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

explore

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Researchers test human milk's ability to repair gut microbiome

DianaBagnoli/GettyImagesForbabieswhoarebreastfed,theirfirstsourceofsustenanceisfilledwithproteins,su

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

Bird flu reported in person exposed to presumably infected cattle

RodrigoAbd/APTexashealthofficialsreportedMondaythatanindividualwhohadbeenincontactwithcattlehascontr

WSS

comprehensive

comprehensive

leisure time

explore

Bird flu reported in person exposed to presumably infected cattle